Home ePRO System for Cancer
Trial Summary
What is the purpose of this trial?
1) Evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. It seems likely that you can continue your current treatments, as the trial involves patients already receiving chemotherapy, targeted therapy, and immunotherapy.
What data supports the effectiveness of the Home ePRO System for Cancer treatment?
Research shows that using electronic patient-reported outcomes (ePRO) systems for symptom monitoring in cancer patients can lead to better quality of life and improved survival rates. Additionally, ePRO systems have been associated with better clinical outcomes and higher patient satisfaction during chemotherapy.12345
Is the Home ePRO System for Cancer safe for humans?
Research on similar systems, like the Advanced Symptom Management System (ASyMS) and other electronic patient-reported outcomes (ePRO) platforms, shows they are generally safe and well-accepted by patients and clinicians. These systems help monitor symptoms during cancer treatment and have been used without major safety concerns, improving patient satisfaction and care.26789
How is the Home ePRO System for Cancer different from other treatments?
The Home ePRO System for Cancer is unique because it uses electronic patient-reported outcomes (ePRO) to remotely monitor symptoms, which can improve quality of life and survival for cancer patients. Unlike traditional treatments that focus solely on medication, this system allows for real-time symptom tracking and management, enhancing patient care through technology.23567
Eligibility Criteria
This trial is for cancer patients aged 18 or older who are receiving chemotherapy, targeted therapy, or immunotherapy at the participating institution from 2019 to 2026. It's designed to assess a home electronic Patient-Reported Outcomes (ePRO) system.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implementation
Implementation of navigator-delivered Home ePRO for all cancer patients receiving chemotherapy
Evaluation
Evaluation of implementation outcomes, barriers, facilitators, and patient-level outcomes
Follow-up
Participants are monitored for safety and effectiveness after implementation
Treatment Details
Interventions
- Navigator-delivered ePRO System
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
University of South Alabama
Collaborator